Pomerantz Law Firm Investigates Securities Fraud Claims Against Journey Medical Corporation
Pomerantz LLP is investigating potential securities fraud involving Journey Medical Corporation (DERM) following a significant stock price drop after the company's March 25, 2026 earnings report. The firm is seeking to represent investors who may have suffered losses due to alleged unlawful business practices by Journey's management and board. The stock fell 30.01% to $4.78 per share following the disclosure.
Topics: class action financial reporting reimbursement issues securities fraud stock price drop